HAE:NYSEHaemonetics Corporation Analysis
Data as of 2026-05-21 - not real-time
$61.94
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Haemonetics (HAE) is trading at $61.94, comfortably above its 20‑day SMA ($57.20) and 50‑day SMA ($58.08) but still below the 200‑day SMA ($62.24), indicating a short‑term pull‑back within a longer‑term bearish backdrop. Technical signals are mixed: the RSI sits at 61 (neutral), the MACD histogram is positive (bullish) while the overall trend is flagged as bearish, and volume is increasing, suggesting renewed buying interest.
Fundamentally, the stock appears undervalued with a DCF fair‑value estimate of $84.48, implying roughly 29% upside, and a forward PE of 10.7 versus an industry average of 27.3. Recent earnings beat, modest revenue growth (≈5%) and expanding operating cash flow reinforce the upside thesis, though high debt‑to‑equity (≈154%) and a 30‑day volatility of ~48% flag notable risk.
Fundamentally, the stock appears undervalued with a DCF fair‑value estimate of $84.48, implying roughly 29% upside, and a forward PE of 10.7 versus an industry average of 27.3. Recent earnings beat, modest revenue growth (≈5%) and expanding operating cash flow reinforce the upside thesis, though high debt‑to‑equity (≈154%) and a 30‑day volatility of ~48% flag notable risk.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 7/10
Key Factors
- Q4 earnings beat and revenue acceleration
- Positive MACD histogram and rising volume
- Immediate upside versus DCF fair value
Medium Term
1–3 yearsNeutral
Model confidence: 6/10
Key Factors
- Price still below 200‑day SMA indicating lingering bearish bias
- Strong operating cash flow supporting earnings stability
- Elevated volatility and high debt levels require monitoring
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Significant long‑term upside potential (~30% to fair value)
- Recurring revenue from plasma and blood‑management platforms
- Low beta and defensive healthcare exposure
Key Metrics & Analysis
Financial Health
Revenue Growth4.80%
Profit Margin7.29%
P/E Ratio30.2
ROE12.03%
ROA6.46%
Debt/Equity153.78
P/B Ratio3.2
Op. Cash Flow$293.2M
Free Cash Flow$301.4M
Industry P/E27.3
Technical Analysis
TrendBearish
RSI61.1
Support$51.00
Resistance$62.18
MA 20$57.20
MA 50$58.08
MA 200$62.24
MACDBullish
VolumeIncreasing
Fear & Greed Index91.5
Valuation
Fair Value$84.48
Target Price$80.20
Upside/Downside29.48%
GradeUndervalued
TypeBlend
Risk Assessment
Beta0.42
Volatility47.62%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.